Multiple anticholinergic medication use and risk of hospital admission for confusion or dementia

Journal of the American Geriatrics Society

Volumn 62, Issue 10, 2014, Pages 1916-1922

  Kalisch Ellett, Lisa M ^a   Pratt, Nicole L ^a   Ramsay, Emmae N ^a   Barratt, John D ^a   Roughead, Elizabeth E ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

anticholinergic medication; confusion; elderly; hospitalization

Indexed keywords

AMANTADINE; AMITRIPTYLINE; ATROPINE; BACLOFEN; BENZATROPINE; BIPERIDEN; CARBAMAZEPINE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOMIPRAMINE; DISOPYRAMIDE; DOSULEPIN; DOXEPIN; HALOPERIDOL; IMIPRAMINE; LOPERAMIDE; NORTRIPTYLINE; OLANZAPINE; OXYBUTYNIN; PALIPERIDONE; PAROXETINE; PERICIAZINE; PIZOTIFEN; PROCHLORPERAZINE; PROPANTHELINE BROMIDE; QUETIAPINE; RISPERIDONE; TRIFLUOPERAZINE; TRIHEXYPHENIDYL; ZIPRASIDONE;

AGED; ANTICHOLINERGIC EFFECT; ARTICLE; COHORT ANALYSIS; CONFUSION; DEMENTIA; DRUG USE; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY ANALYSIS; VERY ELDERLY; ANTICHOLINERGIC SYNDROME; AUSTRALIA; CHEMICALLY INDUCED; DRUG COMBINATION; EPIDEMIOLOGY; INCIDENCE; RISK; STATISTICS AND NUMERICAL DATA;

AGED, 80 AND OVER; ANTICHOLINERGIC SYNDROME; AUSTRALIA; CHOLINERGIC ANTAGONISTS; COHORT STUDIES; CONFUSION; DEMENTIA; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; RETROSPECTIVE STUDIES; RISK;

EID: 84911969271     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/jgs.13054     Document Type: Article

References (32)

1. Schubert CC, Boustani M, Callahan CM, et al. Comorbidity profile of dementia patients in primary care: Are they sicker? J Am Geriatr Soc 2006; 54: 104-109.
2. Campbell N, Boustani M, Limbil T, et al. The cognitive impact of anticholinergics: A clinical review. Clin Interv Aging 2009; 4: 225-233.
3. Nishtala PS, Fois RA, McLachlan AJ, et al. Anticholinergic activity of commonly prescribed medications and neuropsychiatric adverse events in older people. J Clin Pharmacol 2009; 49: 1176-1184.
4. Boustani M, Campbell N, Munger S, et al. Impact of anticholinergics on the aging brain: A review and practical application. Aging Health 2008; 4: 311-320.
5. Ancelin ML, Artero S, Portet F, et al. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: Longitudinal cohort study. BMJ 2006; 332: 455-459.
6. Carrière I, Fourrier-Reglat A, Dartigues J-F, et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: The 3-City Study. Arch Intern Med 2009; 169: 1317-1324.
7. Ness J, Hoth A, Barnett MJ, et al. Anticholinergic medications in community-dwelling older veterans: Prevalence of anticholinergic symptoms, symptom burden, and adverse drug events. Am J Geriatr Pharmacother 2006; 4: 42-51.
8. Mulsant BH, Pollock BG, Kirshner M, et al. Serum anticholinergic activity in a community-based sample of older adults: Relationship with cognitive performance. Arch Gen Psychiatry 2003; 60: 198-203.
9. Lampela P, Lavikainen P, Garcia-Horsman JA, et al. Anticholinergic drug use, serum anticholinergic activity, and adverse drug events among older people: A population-based study. Drugs Aging 2013; 30: 321-330.
10. Gnjidic D, Cumming RG, Le Couteur DG, et al. Drug Burden Index and physical function in older Australian men. Br J Clin Pharmacol 2009; 68: 97-105.
11. Uusvaara J, Pitkala KH, Kautiainen H, et al. Association of anticholinergic drugs with hospitalization and mortality among older cardiovascular patients: A prospective study. Drugs Aging 2011; 28: 131-138.
12. Chavant F, Favrelière S, Lafay-Chebassier C, et al. Memory disorders associated with consumption of drugs: Updating through a case/noncase study in the French pharmacovigilance database. Br J Clin Pharmacol 2011; 72: 898-904.
13. Cancelli I, Beltrame M, Gigli GL, et al. Drugs with anticholinergic properties: Cognitive and neuropsychiatric side-effects in elderly patients. Neurol Sci 2009; 30: 87-92.
14. Sendelbach S, Guthrie PF, Schoenfelder D,. Acute confusion/delirium. Identification, assessment, treatment and prevention. J Gerontol Nurs 2009; 35: 11-18.
15. Rudolph JL, Salow MJ, Angelini MC, et al. The Anticholinergic Risk Scale and anticholinergic adverse effects in older persons. Arch Intern Med 2008; 168: 508-513.
16. Carnahan RM, Lund BC, Perry PJ, et al. The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: Associations with serum anticholinergic activity. J Clin Pharmacol 2006; 46: 1481-1486.
17. Fox C, Richardson K, Maidment I, et al. Anticholinergic medication use and cognitive impairment in the older population: The medical research council cognitive function and ageing study. J Am Geriatr Soc 2011; 59: 1477-1483.
18. Pasina L, Djade CD, Lucca U, et al. Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: Comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale: Results from the REPOSI Study. Drugs Aging 2013; 30: 103-112.
19. Cai X, Campbell N, Khan B, et al. Long-term anticholinergic use and the aging brain. Alzheimers Dement 2013; 9: 377-385.
20. Best O, Gnjidic D, Hilmer SN, et al. Investigating polypharmacy and Drug Burden Index in hospitalised older people. Intern Med J 2013; 43: 912-918.
21. Anatomical Therapeutic Chemical Code Classification Index with Defined Daily Doses. Oslo: World Health Organization Collaborating Centre for Drug Statistics Methodology; 2004 [on-line]. Available at http://www.whocc.no/atcddd/ Accessed February 4, 2004.
22. Australian Government Department of Health and Ageing. Pharmaceutical Benefits Scheme. 2011 [on-line]. Available at http://www.pbs.gov.au/browse/publications Accessed July 31, 2014.
23. International Statistical Classification of Diseases and Related Health Problems, 10th Revision. Geneva: World Health Organization; 2007 [on-line]. Available at http://apps.who.int/classifications/apps/icd/icd10online/ Accessed July 31, 2014.
24. Hilmer SN, Mager DE, Simonsick EM, et al. A drug burden index to define the functional burden of medications in older people. Arch Intern Med 2007; 167: 781-787.
25. Information Paper: Census of Population and Housing. Socio-Economic Indexes for Areas, Australia, 2011, ABS cat. no. 2039.0. Canberra: Australian Bureau of Statistics, 2003.
26. Vitry A, Wong S, Roughead EE, et al. Validity of medication-based co-morbidity indices in the Australian elderly population. Aust N Z J Public Health 2009; 33: 126-130.
27. Ball P, Morrisey H, Pilotto L,. Anticholinergic burden assessed using general practice electronic records. J Pharm Pract Res 2013; 43: 202-205.
28. Lechevallier-Michel N, Molimard M, Dartigues J-F, et al. Drugs with anticholinergic properties and cognitive performance in the elderly: Results from the PAQUID Study. Br J Clin Pharmacol 2004; 59: 143-151.
29. Kalisch LM, Caughey GE, Barratt JD, et al. Prevalence of preventable medication-related hospitalizations in Australia: An opportunity to reduce harm. Int J Qual Health Care 2012; 24: 239-249.
30. Hufschmidt A, Shabarin V, Zimmer T,. Drug-induced confusional states: The usual suspects? Acta Neurol Scand 2009; 120: 436-438.
31. The American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc 2012; 2012: 616-631.
32. Australian Hospital Statistics 2012-13. Health Services Series no. 54. Cat. no. HSE 145. Canberra: Australian Institute of Health and Welfare, 2014.